Literature DB >> 7504098

Precipitated withdrawal by pentazocine in methadone-maintained volunteers.

E C Strain1, K L Preston, I A Liebson, G E Bigelow.   

Abstract

Pentazocine is a partial mu agonist opioid with one-half to one-sixth the parenteral analgesic potency of morphine. The purpose of this study was to characterize the effects of pentazocine in comparison to naloxone (an opioid antagonist), hydromorphone (an opioid mu agonist) and saline in methadone-dependent volunteers by using the same experimental methods used previously in the study of the opioid analgesics buprenorphine, butorphanol and nalbuphine. In a residential laboratory, five volunteer male opioid abusers, maintained on 30 mg p.o. of methadone daily, underwent pharmacological challenges 2 to 3 times per week. Pharmacological challenges consisted of a double-blind i.m. injection of: pentazocine (dose range 7.5-120 mg), hydromorphone (5 and 10 mg), naloxone (0.1 and 0.2 mg) or saline. Injections were given 20 hr after the last dose of methadone. Measures included physiological indices and self-reports and observer ratings of drug effects. Naloxone and hydromorphone produced characteristic antagonist-like and agonist-like effects, respectively, on subjective, observer and physiological indices. Pentazocine produced primarily antagonist-like effects, with higher doses (> = 60 mg) producing significant elevations of visual analog scale ratings of Drug Effects, Bad Effects and Sick; of observer ratings of piloerection, restlessness and adjective scores of opioid withdrawal; as well as increases in blood pressure, heart rate and pupil diameter and decreases in skin temperature. Similar to the previous study of butorphanol, the specific profile of effects produced by pentazocine differed from that produced by naloxone, suggesting non-mu effects may modulate the mu effects of pentazocine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504098

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.

Authors:  James Rosado; Sharon L Walsh; George E Bigelow; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2007-05-22       Impact factor: 4.492

2.  Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.

Authors:  Angela N Duke; Christopher J Correia; Sharon L Walsh; George E Bigelow; Eric C Strain
Journal:  Psychopharmacology (Berl)       Date:  2010-06-25       Impact factor: 4.530

3.  The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.

Authors:  Lisa S Middleton; Paul A Nuzzo; Michelle R Lofwall; David E Moody; Sharon L Walsh
Journal:  Addiction       Date:  2011-05-03       Impact factor: 6.526

4.  Elevated customary alcohol consumption attenuates opioid effects.

Authors:  Monique M Cherrier; Danny D Shen; Laura Shireman; Andrew J Saxon; Tracy Simpson; Alex Men; Preetma Kooner; Gregory W Terman
Journal:  Pharmacol Biochem Behav       Date:  2021-11-04       Impact factor: 3.533

5.  Effects of buprenorphine and methadone in methadone-maintained subjects.

Authors:  S L Walsh; H L June; K J Schuh; K L Preston; G E Bigelow; M L Stitzer
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

Review 6.  Treatment of opioid-dependent pregnant women: clinical and research issues.

Authors:  Hendree E Jones; Peter R Martin; Sarah H Heil; Karol Kaltenbach; Peter Selby; Mara G Coyle; Susan M Stine; Kevin E O'Grady; Amelia M Arria; Gabriele Fischer
Journal:  J Subst Abuse Treat       Date:  2008-01-14

7.  Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.

Authors:  Monique M Cherrier; John K Amory; Mary Ersek; Linda Risler; Danny D Shen
Journal:  J Pain       Date:  2009-09-02       Impact factor: 5.820

Review 8.  Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.

Authors:  Shane W Kaski; Allison N White; Joshua D Gross; David P Siderovski
Journal:  Anesth Analg       Date:  2021-02-01       Impact factor: 6.627

Review 9.  Practical considerations for the clinical use of buprenorphine.

Authors:  Hendree E Jones
Journal:  Sci Pract Perspect       Date:  2004-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.